PHARMACEUTICAL IMPORT BUSINESS GROWTH
Grow and scale your pharmaceutical import business
HCPA helps pharmaceutical importers identify product opportunities, reach suitable Australian buyers and distribution partners, and build overseas brand relationships that fit their regulatory and commercial model.

Growth in pharmaceutical importing can come from adding the right products, strengthening overseas supplier relationships and expanding the channels through which those products reach the Australian market.
As the portfolio grows, the business also needs the regulatory, distribution and operational capacity to support those products effectively. HCPA can help you identify the strongest growth opportunities and build the commercial and regulatory strategy needed to pursue them.
Work with a senior consultant embedded in your leadership team
Your senior consultant brings deep experience across regulated industries, working alongside your leadership team to support strategic decisions, operational improvement and sustainable growth.
Draw on the experience of 200+ industry consultants
Benefit from the collective regulatory, operational and commercial experience of our team of 200+ consultants, helping you identify risks, avoid common growth mistakes and make better-informed decisions.

$2.1B+
Apply insights from 16,000 businesses we have supported
We bring practical insights from supporting 16,000 businesses across regulated industries, whose businesses have collectively generated more than $3.8 billion in revenue.

Completion
Action Required





16,000+ Businesses are growing faster
First Client Guarantee
Grow with regulatory confidence

Completion
Action Required





16,000+ Businesses are growing faster
First Client Guarantee

$2.1B+

Completion
Action Required





16,000+ Businesses are growing faster
First Client Guarantee
Where is the potential to grow a pharmaceutical import business?
For established pharmaceutical importers, growth can come from adding the right products, strengthening overseas supplier relationships and building more effective Australian distribution channels.
Explore emerging product opportunities
New ingredients, formulations and product categories can create opportunities where Australian demand is emerging. The strongest opportunities combine genuine market potential with a workable regulatory pathway.
Identify off-patent opportunities
Patent expiry can create opportunities for competing products to enter established markets. Importers may be able to work with overseas manufacturers or brands to prepare suitable products for Australia.
Target proven market demand
Existing sales and competitor activity can help indicate where Australian demand already exists. This can reveal opportunities for an alternative product or stronger distribution proposition.
Turn product opportunities into sustainable growth
A stronger pharmaceutical import growth strategy can help your business work towards:
a stronger and more commercially viable product portfolio
better access to suitable Australian buyers and distribution channels
stronger relationships with overseas brands and manufacturers
more successful product launches
greater recurring product revenue
better margins across products and channels
growth supported by sufficient regulatory and operational capacity
HCPA can help you identify which products, partners and channels offer the strongest potential and build a strategy for turning those opportunities into sustainable growth.
Is your pharmaceutical import business ready to grow?
Can your regulatory and sponsor systems support additional products?
Do you have enough operational capacity to manage new suppliers and ARTG obligations?
Can your storage, logistics and traceability systems support higher volumes or more complex products?
Do your distribution partners have capacity to support further growth?
Can inventory and working capital support a larger portfolio?
Will the additional products strengthen revenue and margin rather than simply add complexity?

How HCPA supports sustainable pharmaceutical import growth
Growing a pharmaceutical import business means expanding the portfolio and distribution network without losing sight of the regulatory and operational capacity needed to support them.
As the portfolio grows, so do the demands across sponsor obligations, overseas manufacturer oversight, inventory, distribution, traceability and working capital. HCPA helps you consider these factors together so commercial growth does not outpace the systems supporting it.
Identify growth opportunities
HCPA assesses your existing portfolio, target markets, supplier relationships and commercial objectives to identify where new products or brand opportunities may fit.
Strengthen routes to market
We assess Australian buyers, distribution channels and commercial partnerships to determine how suitable products can reach the right markets effectively.
Prepare your portfolio to scale
HCPA considers regulatory capacity, sponsor obligations, supply arrangements, logistics and working capital so the business can support a larger portfolio sustainably.
How HCPA helps you grow and scale sustainably
Assess your current position
Review your portfolio, target markets, distribution model, supplier relationships and regulatory and operational capacity.
Identify growth opportunities
Assess products, overseas brands, Australian buyers and distribution pathways to identify the opportunities that best fit your business.
Develop the growth strategy
Build a practical plan around product expansion, supplier relationships, distribution channels, market positioning and regulatory capacity.
Prepare for growth
Strengthen the regulatory, operational and commercial systems needed to support additional products and partnerships as the business scales.
HCPA’s First Client Guarantee
Backed by HCPA’s First Client Guarantee
For eligible businesses, HCPA’s support extends beyond developing the growth strategy. Once your business is operational, HCPA works with you to secure your first paying client within 12 months. If that outcome is not achieved and you have met the requirements of the guarantee, HCPA continues working with you at no additional cost until your first paying client is secured.
What could sustainable growth mean for your pharmaceutical import business?
At 30 June 2025, the PBS included 949 different medicines across 5,164 brands, highlighting the breadth and competition within Australia’s medicines market.
Sustainable growth is less about adding the greatest number of products and more about building a portfolio that strengthens revenue, margin and market position without creating unnecessary regulatory or operational complexity.
HCPA can help you work towards:
qualified product opportunities
new brand and manufacturer agreements
buyer and distribution partnerships
successful product launches
recurring product revenue
margin by product or channel
repeat orders and customer retention
The opportunity is to grow a stronger portfolio through the products, channels and partnerships that create the greatest commercial value, while maintaining the regulatory capacity needed to support them.
Frequently asked questions about pharmaceutical import growth
How can a pharmaceutical importer identify suitable Australian buyers and distribution channels?
Start with the product and the customers it needs to reach, then identify wholesalers and distribution partners whose market reach, handling capabilities and commercial model fit that product.
Consider customer access, expected volumes, margins, storage requirements, logistics and traceability rather than reach alone.
HCPA can help you map the route to market and identify the partners most relevant to your portfolio.
What should I demonstrate to secure an Australian distribution agreement with an overseas pharmaceutical brand?
Demonstrate a credible plan for bringing the product into Australia and developing its market.
That can include your sponsor and ARTG capability, target customers, distribution strategy, supply-chain arrangements and commercial plan.
The overseas brand should be able to see both how you intend to grow the product and how you will support the responsibilities associated with supplying it in Australia.
What should a pharmaceutical importer marketing strategy include?
A pharmaceutical importer marketing strategy should define the products and customer segments the business is best positioned to serve, then identify the market proposition, distribution channels and business-development activity needed to reach them.
The focus should be on generating commercially relevant opportunities rather than simply more enquiries.
How can a pharmaceutical importer expand its product portfolio?
Opportunities can come from emerging products and ingredients, products approaching patent expiry and categories where existing competitors demonstrate strong demand.
The strongest additions are those that complement the existing portfolio, distribution network and commercial strategy.
Can products coming off patent create opportunities for pharmaceutical importers?
Potentially. Patent expiry can create opportunities for competing products to enter an established market where the importer can source a suitable product and establish the necessary Australian regulatory pathway.
The opportunity should still be assessed against competition, pricing and expected demand.
How should an established importer assess its next product opportunity?
Consider how the product fits your existing portfolio, customers, supplier relationships and distribution network.
Also assess whether the business has enough regulatory, operational and working-capital capacity to support the additional product without weakening the performance of the existing portfolio.
What types of partners might a pharmaceutical importer need?
Depending on the model, an importer may work with overseas manufacturers or pharmaceutical brands, along with Australian logistics providers, wholesalers and distribution partners. HCPA can help identify the types of partnerships needed to support the portfolio and route to market.
Does being the Australian sponsor affect how I grow the business?
Yes. Growth in the product portfolio can also increase the sponsor responsibilities the business needs to manage.
Each additional product can add regulatory, quality and ongoing oversight responsibilities for the sponsor.
Regulatory capacity therefore needs to grow alongside the commercial portfolio.
Related pharmaceutical importing resources
Starting your import business
Ready to start your pharmaceutical import business?
Managingongoing compliance
Need help keeping your import operation compliant?
What Our Clients Say

